Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Samuel K. Bouchillon"'
Autor:
James A. Karlowsky, Samuel K. Bouchillon, Amina Benaouda, Nabila Soraa, Khalid Zerouali, Naglaa Mohamed, Taha Alami, Daniel F. Sahm
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 30, Iss , Pp 23-30 (2022)
ABSTRACT: Objectives: To report reference method antimicrobial susceptibility testing results for recent clinical isolates of Gram-negative bacilli from Morocco. Methods: CLSI (Clinical and Laboratory Standards Institute) broth microdilution antimicr
Externí odkaz:
https://doaj.org/article/30689828b67846578b9c9bacc1a23dc7
Autor:
James A Karlowsky, Samuel K Bouchillon, Ramy El Mahdy Kotb, Naglaa Mohamed, Gregory G Stone, Daniel F Sahm
Publikováno v:
JAC-Antimicrobial Resistance. 4
Objectives To determine the in vitro susceptibility of Enterobacterales (n = 5457) and Pseudomonas aeruginosa (n = 1949) isolated from hospitalized patients in Africa (three countries) and the Middle East (five countries) in 2018–20 to a panel of 1
Autor:
James A. Karlowsky, Samuel K. Bouchillon, Amina Benaouda, Nabila Soraa, Khalid Zerouali, Naglaa Mohamed, Taha Alami, Daniel F. Sahm
Publikováno v:
Journal of global antimicrobial resistance. 30
To report reference method antimicrobial susceptibility testing results for recent clinical isolates of Gram-negative bacilli from Morocco.CLSI (Clinical and Laboratory Standards Institute) broth microdilution antimicrobial susceptibility testing was
Autor:
Naglaa S. Mohamed, Samuel K. Bouchillon, Gregory G. Stone, Ramy Kotb, Daniel F. Sahm, James A. Karlowsky
Publikováno v:
JAC-Antimicrobial Resistance
Objectives To assess the in vitro activity of ceftazidime/avibactam against a recent, 2015–18, collection of clinical isolates of Gram-negative bacilli from Middle Eastern and African countries with a focus on isolates from ICUs and with MDR and di
Publikováno v:
Antimicrob Agents Chemother
WCK 5222 (cefepime-zidebactam, 2 g + 1g, every 8 h [q8h]) is in clinical development for the treatment of infections caused by carbapenem-resistant and multidrug-resistant (MDR) Gram-negative bacilli. We determined the in vitro susceptibility of 1,38
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 89:151-157
Clinical isolates of Staphylococcus aureus (n=3929) collected by 54 medical center laboratories in 12 countries in 2014-2016 were tested for in vitro susceptibility to tedizolid, linezolid, and 11 comparators using Clinical and Laboratory Standards I
Autor:
Gregory G. Stone, Krystyna M. Kazmierczak, Samuel K. Bouchillon, James A. Karlowsky, Boudewijn L. M. de Jonge, Daniel F. Sahm
The in vitro activities of ceftazidime-avibactam and comparators against 9,149 isolates of Enterobacteriaceae and 2,038 isolates of Pseudomonas aeruginosa collected by 42 medical centers in nine countries in the Asia-Pacific region from 2012 to 2015
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de94cb92dd8e69055d08b2f8decfe036
https://europepmc.org/articles/PMC6437529/
https://europepmc.org/articles/PMC6437529/
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 35:1933-1939
Tedizolid is an oxazolidinone with an antimicrobial in vitro potency advantage against Gram-positive bacterial pathogens compared to other currently marketed drugs in this class, including linezolid. Tedizolid was compared to linezolid when tested ag
Autor:
Sharon Rabine, Meredith Hackel, Douglas J. Biedenbach, Daniel F. Sahm, Samuel K. Bouchillon, Krystyna M. Kazmierczak, Patricia A. Bradford, Boudewijn L. M. de Jonge
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:4490-4500
The Klebsiella pneumoniae carbapenemase (KPC), first described in the United States in 1996, is now a widespread global problem in several Gram-negative species. A worldwide surveillance study collected Gram-negative pathogens from 202 global sites i
Autor:
Gregory G. Stone, Douglas J. Biedenbach, Samuel K. Bouchillon, Krystyna M. Kazmierczak, Boudewijn L. M. de Jonge, Meredith Hackel, Daryl J. Hoban
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:4677-4683
Increasing resistance in Gram-negative bacilli, including Klebsiella spp., has reduced the utility of broad-spectrum cephalosporins. Avibactam, a novel non-β-lactam β-lactamase inhibitor, protects β-lactams from hydrolysis by Gram-negative bacteri